[go: up one dir, main page]

BR9811861A - Polipeptìdeos de fatores de crescimento ligantes de heparina (fclh) - Google Patents

Polipeptìdeos de fatores de crescimento ligantes de heparina (fclh)

Info

Publication number
BR9811861A
BR9811861A BR9811861-7A BR9811861A BR9811861A BR 9811861 A BR9811861 A BR 9811861A BR 9811861 A BR9811861 A BR 9811861A BR 9811861 A BR9811861 A BR 9811861A
Authority
BR
Brazil
Prior art keywords
fclh
heparin
polypeptides
binding growth
growth factor
Prior art date
Application number
BR9811861-7A
Other languages
English (en)
Inventor
David A Brigstock
Paul A Harding
Original Assignee
Childrens Hosp Res Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hosp Res Foundation filed Critical Childrens Hosp Res Foundation
Publication of BR9811861A publication Critical patent/BR9811861A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Patente de Invenção: <B>"POLIPEPTìDEOS DE FATORES DE CRESCIMENTO LIGANTES DE HEPARINA (FCLH)"<D>. Polipeptídeos de fatores de crescimento ligantes de heparina substancialmente puros (FsCLH), ácido nucléicos codificadores dos FsCLH e anticorpos que se ligam aos FsCLH da invenção são fornecidos. Os polipeptídeos do FCLH são úteis nos métodos para a indução de formação de osso, cartilagem e tecidos, para o crescimento e desenvolvimento do endométrio e na aceleração da cicatrização de ferimentos.
BR9811861-7A 1997-08-07 1998-08-06 Polipeptìdeos de fatores de crescimento ligantes de heparina (fclh) BR9811861A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/908,526 US5876730A (en) 1997-08-07 1997-08-07 Heparin-binding growth factor (HBGF) polypeptides
PCT/US1998/016423 WO1999007407A1 (en) 1997-08-07 1998-08-06 Heparin-binding growth factor (hbgf) polypeptides

Publications (1)

Publication Number Publication Date
BR9811861A true BR9811861A (pt) 2000-08-15

Family

ID=25425931

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811861-7A BR9811861A (pt) 1997-08-07 1998-08-06 Polipeptìdeos de fatores de crescimento ligantes de heparina (fclh)

Country Status (15)

Country Link
US (3) US5876730A (pt)
EP (1) EP1003545B1 (pt)
JP (2) JP4638027B2 (pt)
CN (1) CN1276729A (pt)
AT (1) ATE395927T1 (pt)
AU (1) AU744585B2 (pt)
BR (1) BR9811861A (pt)
CA (1) CA2299411A1 (pt)
DE (1) DE69839516D1 (pt)
DK (1) DK1003545T3 (pt)
ES (1) ES2307322T3 (pt)
IL (1) IL134330A0 (pt)
NO (1) NO20000579L (pt)
PT (1) PT1003545E (pt)
WO (1) WO1999007407A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033878A1 (en) 1997-12-25 1999-07-08 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
WO2000020869A1 (en) * 1998-10-06 2000-04-13 Georgetown University Detection of pleiotrophin
US7141384B1 (en) 1998-10-06 2006-11-28 Georgetown University Detection of pleiotrophin
US7115390B1 (en) * 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
US6492129B1 (en) * 1998-12-14 2002-12-10 University Of Miami Fragments of connective tissue growth factor that induce extracellular matrix synthesis, collagen synthesis and/or myofibroblast differentiation
US7671018B2 (en) 2000-08-30 2010-03-02 University Of Delaware Delivery system for heparin-binding growth factors
US7297343B2 (en) * 2001-07-31 2007-11-20 Biosurface Engineering Technologies, Inc. Bioactive medical films
FR2828104B1 (fr) * 2001-08-01 2005-06-24 Chu Montpellier Utilisation d'inhibiteurs du facteur de croissance epidermique liant l'heparine ou d'inhibiteurs de ses recepteurs pour la preparation de medicaments utiles pour traiter le myelome
US20030113816A1 (en) * 2001-09-18 2003-06-19 Weitz Stephen L. Methods of assaying connective tissue growth factor
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
GB0225197D0 (en) * 2002-10-30 2002-12-11 Univ Sheffield Surface
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
US20050153395A1 (en) * 2003-09-29 2005-07-14 Children's Hospital Inc. Unique integrin binding site in connective tissue growth factor (CTGF)
PL1715890T3 (pl) 2004-02-11 2009-01-30 Fibrogen Inc CTGF jako cel dla terapii mikroalbinurii u pacjentów z nefropatią cukrzycową
MXPA06012576A (es) 2004-04-28 2007-01-31 Fibrogen Inc Tratamientos para cancer pancreatico.
DE102004021872B3 (de) 2004-05-04 2005-12-22 Infineon Technologies Ag Chipkarte, Verfahren zum Herstellen einer Chipkarte und elektrisch leitfähiges Kontaktierungselement
US20070049739A1 (en) * 2005-08-30 2007-03-01 Biomet Manufacturing Corp. Method and system for extracting blood-derived growth factors
US8946172B2 (en) * 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
CN107083386A (zh) 2008-08-25 2017-08-22 埃克斯雷德制药有限公司 阻止结缔组织生长因子的反义核苷酸及其用途
CN101497656B (zh) * 2009-03-09 2012-08-15 东南大学 与整合素αvβ3具有高结合活性的多肽及其应用
WO2011002525A1 (en) 2009-07-02 2011-01-06 Fibrogen, Inc. Methods for treatment of muscular dystrophy
US9102721B2 (en) 2011-01-21 2015-08-11 Fibrogen, Inc. Therapeutic method
HUE044178T4 (hu) 2011-02-02 2019-10-28 Excaliard Pharmaceuticals Inc Kötõszöveti növekedési faktort (CTGF) célzó antiszensz vegyületek keloidok vagy hipertrófiás hegek kezelési eljárásban történõ alkalmazásra

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235042A (en) 1984-02-29 1993-08-10 The Children's Medical Center Corporation Endothelial cell growth factor
US4868113A (en) * 1986-03-03 1989-09-19 Rorer Biotechnology, Inc. Recombinant DNA vector encoding human endothelial cell growth factor
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85018A0 (en) * 1988-01-03 1988-06-30 Orgenics Ltd Stable chromogenic substrate mixture of indoxyl phosphate and tetrazolium salt,method of making and using same in biological and diagnostic assays
US5225326A (en) * 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
CA2094045A1 (en) 1990-10-16 1992-04-17 Michael Klagsbrun Heparin binding mitogen with egf homology
US5770209A (en) 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5596090A (en) * 1992-07-24 1997-01-21 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human VCAM-1 RNA
EP0804562B1 (en) 1994-07-12 2002-10-09 Human Genome Sciences, Inc. Connective tissue growth factor-2
US5646115A (en) * 1994-10-07 1997-07-08 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
US5607918A (en) 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US7115390B1 (en) * 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof

Also Published As

Publication number Publication date
EP1003545A4 (en) 2002-03-06
IL134330A0 (en) 2001-04-30
ATE395927T1 (de) 2008-06-15
PT1003545E (pt) 2008-08-13
WO1999007407A1 (en) 1999-02-18
US20010007019A1 (en) 2001-07-05
CN1276729A (zh) 2000-12-13
DK1003545T3 (da) 2008-08-25
WO1999007407A9 (en) 1999-05-06
DE69839516D1 (de) 2008-07-03
US5876730A (en) 1999-03-02
ES2307322T3 (es) 2008-11-16
EP1003545A1 (en) 2000-05-31
US7897732B2 (en) 2011-03-01
JP4638027B2 (ja) 2011-02-23
US20110160445A1 (en) 2011-06-30
AU8696298A (en) 1999-03-01
JP2009254370A (ja) 2009-11-05
CA2299411A1 (en) 1999-02-18
JP2001513334A (ja) 2001-09-04
EP1003545B1 (en) 2008-05-21
NO20000579L (no) 2000-02-25
NO20000579D0 (no) 2000-02-04
AU744585B2 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
BR9811861A (pt) Polipeptìdeos de fatores de crescimento ligantes de heparina (fclh)
EE9900611A (et) Osteoprotegeriini siduvad valgud ja retseptorid
DE59708957D1 (de) Chirurgisches instrument zum mechanischen entfernen von knochenzement
BR9813028A (pt) Agonistas de prostaglandina e seu uso para tratar distúrbios nos ossos
DE69500014D1 (de) Widerlager zur Klammerung von weichem Gewebe
BR0106100A (pt) Composição de gesso fixado, artigo, e, método para preparar uma composição de gesso fixado
DK0648838T3 (da) Vævsinhibitor af metalloproteinase type tre (TIMP-3)
DE69837924D1 (de) Chromophoren zur herstellung von neuen tandem-konjugaten
ATE83374T1 (de) Neue galenische form von fenofibrat.
CY1106260T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της ασβεστοποιησεως των οστων
PT93910A (pt) Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula
BR9609424A (pt) Novos peptìdeos, compostos, composição farmacêutica, processo para tratar um tumor em um mamìfero, e, processo para preparar os compostos
DE60130008D1 (de) Proteinkombinationen zur heilung von wunden
EP1007706A4 (en) RNA-BINDING PROTEIN AND BINDING POINT USEFUL FOR THE EXPRESSION OF RECOMBINANT MOLECULES
BR9509172A (pt) Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica
ATE107859T1 (de) Verwendung von antiprogestomimetika zur stimulierung des eisprungs.
ES2164169T3 (es) Proteinas estimulantes de celulas t de pestivirus.
SE9602822D0 (sv) New receptor
BR0114977A (pt) segmentos preferidos de proteìna de filamento neural e métodos para uso dos mesmos
BR9712767A (pt) Expressão especìfica para tecido de proteìna de retinoblastoma
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
ATE254469T1 (de) Verfahren zur verminderung der renalen aufnahme von antikörperfragmenten
BRPI9809078B8 (pt) peptídeo sintético utilizáveis nos testes biológicos para a detecção das infecções devido aos vírus hiv1 do grupo o, composição que os compreende, processo de imunodosagem in vitro e kit de diagnóstico.
BR9812869A (pt) Processo para a preparação de benzofuranonas eventualmente substituìdas
FR2766358B3 (fr) Instrument d&#39;elimination de ciment chirurgical

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A,7AE 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1890 DE 27/03/2007.